Incyte Corporation reported Q1 2026 results on April 28, and the market reacted better than bears expected — yet short sellers are still adding to positions, and options traders are hedging at an intensity not seen in months.
The stock closed Tuesday at $99.10, up 1.4% on the day and 2.4% on the week. That follows a 10% rally over the past month, the kind of move that might ordinarily ease bearish pressure. Instead, short interest has risen 5.9% in the past week to 7.2% of the free float — up from roughly 6.3% in mid-March. The direction is clear: shorts are rebuilding through a price recovery, not retreating from it.
The lending market does not appear to be straining under that demand. Borrow availability remains loose, with cost to borrow down sharply — 34% over the week to just 0.29% annually, its lowest reading in the 30-day window. That matters: cheap, plentiful borrow means no mechanical squeeze pressure. Shorts can add, and do, without friction. The ORTEX short score has nudged above 51 for the first time in recent sessions, climbing from 49.7 to 51.6 over the past fortnight. That crossing of the midpoint is modest but directional.
Options positioning has shifted meaningfully toward the defensive side. The put/call ratio ran at 1.14 through the close — well above its 20-day average of 0.78 and roughly 1.6 standard deviations from the mean. The ratio made a sharp jump around April 22-23, moving from a call-heavy 0.73 to above 1.19 within two sessions, coinciding with the earnings window. That pivot has held. The 52-week high for the ratio is 1.67, so the reading is elevated but not extreme — though it is closer to the upper end of the range than the lower. In short, option buyers paid for protection through the print, and have not rushed to unwind those hedges.
The Street's response to the Q1 print has been constructive but measured. Stifel lifted its target from $120 to $123 maintaining its Buy rating, while Oppenheimer raised its target from $84 to $90 but held at Perform — reflecting a pattern seen across recent weeks where bulls modestly raise ambitions while more cautious voices stay cautious. The mean price target across covering analysts is $108, about 9% above current levels. Jefferies, notably, cut to Hold with a $94 target back in mid-March, and UBS trimmed its target to $94 from $104 around the same time. The company's full-year revenue guidance of $4.7–$4.9 billion sits squarely in focus: the Q1 deep-dive commentary flagged pipeline progress alongside guidance caution, consistent with bulls citing Opzelura and Jakafi durability while bears point to a near-term catalyst calendar that is not especially dense. Factor scores add nuance: EPS momentum over 30 days ranks in the 79th percentile, and the EV/EBIT multiple ranks in the 74th percentile for value — reasonable support for the bull case. Earnings surprise history ranks at 68, suggesting the company has a decent track record of beating estimates.
Insider activity is largely routine. Division President Pablo Cagnoni sold roughly 18,700 shares on April 17 at $96.50 — his third similar-sized sale in three months — consistent with a pre-planned programme rather than a directional signal. Awards were issued to the CEO and CMO in mid-April. On the institutional side, Baker Bros. Advisors held steady at 15.6% of shares, while BlackRock added around 434,000 shares to lift its stake to 9.2% of shares in the most recent reporting period. No dramatic realignment here.
Close peers had a weaker week, with HALO off 7.8% and PTCT down 8.9% — both meaningfully worse than INCY's modest gain. The relative outperformance on the week stands out, even if it follows the specific catalyst of the earnings print rather than any sector-wide re-rating.
The next earnings date is July 28. Between now and then, the key variables to watch are whether the put/call ratio normalises back toward its 20-day average, whether short interest continues to accumulate above 7% of the float despite loose borrow conditions, and whether guidance revisions on Opzelura and the late-stage oncology portfolio shift the analyst consensus from its current holding pattern.
See the live data behind this article on ORTEX.
Open INCY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
